sur ABIVAX (EPA:ABVX)
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax, a clinical-stage biotechnology company, will present three scientific abstracts on its lead drug candidate, obefazimod, at the UEG Week 2024 in Vienna. The presentations will take place from October 12-15, 2024.
Professor Bruce E. Sands will deliver an oral presentation on the Phase 2b efficacy and safety data at weeks 48 and 96 for obefazimod-treated patients with moderately to severely active ulcerative colitis (UC). The study focuses on non-responders at week 8 of the induction phase.
Two moderated poster presentations will discuss corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96, and the impact of obefazimod induction therapy on combined histologic and endoscopic outcomes at week 8 in UC patients.
Abivax aims to advance the treatment paradigm for UC with obefazimod, a once-daily oral therapy. The company's Chief Medical Officer, Fabio Cataldi, MD, highlighted the potential of obefazimod in enhancing UC treatment.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX